Patrick L. Wagner, MD
Departments of Pathology and Laboratory Medicine and Cardiothoracic Surgery, Weill Medical College of Cornell University, New York, NY

Sven Perner, MD, PhD
Department of Pathology and Laboratory Medicine, Weill Medical College of Cornell University, New York, NY

David S. Rickman, PhD
Department of Pathology and Laboratory Medicine, Weill Medical College of Cornell University, New York, NY

Christopher J. LaFargue
Department of Pathology and Laboratory Medicine, Weill Medical College of Cornell University, New York, NY

Naoki Kitabayashi
Department of Pathology and Laboratory Medicine, Weill Medical College of Cornell University, New York, NY

Stephen F. Johnstone
Department of Pathology and Laboratory Medicine, Weill Medical College of Cornell University, New York, NY

Barbara A. Weir, PhD
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA

Matthew Meyerson, MD, PhD
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA

Nasser K. Altorki, MD
Department of Cardiothoracic Surgery, Weill Medical College of Cornell University, New York, NY

Mark A. Rubin, MD
Department of Pathology and Laboratory Medicine, Weill Medical College of Cornell University, New York, NY

Keywords: Lung cancer; KRAS; EGFR; p21; Gene amplification

Upon completion of this activity, you will be able to:

• describe the significance of KRAS mutation in non-small cell lung carcinoma (NSCLC).
• distinguish between KRAS mutation and KRAS amplification in NSCLC.
• describe the prevalence of KRAS amplification in NSCLC.
• describe the relationship between KRAS amplification and p21 protein expression in NSCLC.